In April 2025, the U.S. DOGE Service implemented deep personnel cuts at the Food and Drug Administration, eliminating 3,500 positions and triggering further departures. More than a year later, the agency has attempted to hire back over 2,000 staff but remains constrained by the same centralized workforce changes that followed the cuts.
According to reporting summarized in Morning Rounds, DOGE’s centralization of human resources functions created bottlenecks. Hundreds of potential new hires are reportedly stalled in pre-onboarding, and routine administrative processes such as purchase approvals and travel payments have deteriorated. An FDA spokesperson emphasized ongoing hiring efforts, but multiple internal sources described operational paralysis. These staffing and administrative problems continue to impede the agency’s ability to restore capacity.
Researchers have advanced the use of human cerebral organoids — three-dimensional brain-like structures grown from human stem cells — by implanting them into mice that had portions of brain tissue removed. The resulting animals reportedly have brains that are half-human by volume. Across standard memory and motor tests, the neuro‑chimeric mice performed approximately like control mice, but extended open-field observations revealed important differences not captured by those tasks.
The work builds on improved methods for growing organoids and raises scientific and ethical questions about the utility and limits of such models. The Morning Rounds summary pointed readers to more detailed reporting on the technical advances and the broader debate about whether and how to use neuro‑chimeric animals in research.
A January study published in Science analyzed government mortality statistics, DEA seizure data, and social media signals to argue that declining fentanyl potency — potentially driven by Chinese enforcement — could explain a recent fall in U.S. opioid overdose deaths. A subsequent replication effort, published in Science Advances and summarized in Morning Rounds, did not reproduce that conclusion.
The replication authors wrote that “a simplistic supply shock is not supported by the evidence.” They reported that measured increases in fentanyl purity across the country did not align with a national decrease in overdose rates. Although some association was observed between declining purity and overdoses in some analyses, that pattern coincided with other unrelated trends, undermining a straightforward causal interpretation.
The replication team also highlighted two key methodological caveats:
DEA sampling changes: The DEA has acknowledged that a reported rise in fentanyl purity in seized samples likely resulted from an alteration in its sampling plan. That change could have biased purity estimates derived from seizure data and thus affected analyses relying on those measures.
Geographic heterogeneity and timing: The replication authors emphasized substantial regional variation in both drug supply and overdose trends. In several regions, declines in overdose deaths preceded the documented drops in potency, which challenges temporal causation. The authors argued that aggregating data nationally can obscure important local patterns and concurrent factors influencing mortality.
The Morning Rounds summary did not report additional methodological details, effect sizes, or statistical results from either the original Science paper or the Science Advances replication. Those specifics were not provided in the source summary and would require consulting the original publications for full study methods and quantitative findings.
The World Health Organization reported cautious optimism about the trajectory of an Ebola outbreak in the Democratic Republic of the Congo. At the time of the Morning Rounds summary, the outbreak had resulted in several thousand confirmed cases and thousands of deaths; the WHO noted that transmission rates were declining in most affected provinces but stressed that months of work remain to fully control the event.
The outbreak was attributed to the Bundibugyo species of Ebola and represented one of the larger recorded outbreaks. The WHO indicated plans for a Phase 3 randomized clinical trial of Ebola vaccines to begin within a short timeframe. The Morning Rounds item framed the update as cautiously encouraging while underscoring that substantial public health efforts are still needed.
The Morning Rounds roundup also highlighted several other items of clinical and policy interest:
Nomination hearings examined whether a senior federal health official would act independently from the health secretary, with senators questioning his potential to resist policy directions on vaccination that have been controversial.
A successful, complex surgical separation of conjoined craniopagus twins was described; the operation involved many specialists and staged skull repairs for the twins.
The newsletter curated additional reading on topics ranging from reproductive health access maps to shifts in psychiatric diagnosis usage and impacts of policy changes on biotech sectors.
Taken together, the items summarized in Morning Rounds illustrate intersecting challenges in public health surveillance, regulatory capacity, biomedical research ethics, and clinical care. In the specific case of opioid mortality trends, the reporting highlights that attributing national declines in overdose deaths to a single change in fentanyl supply or potency is not supported by the replication analysis summarized here; the DEA’s sampling changes and regional heterogeneity are important qualifiers that require careful consideration and further study.